319 active not recruiting. 319 Phase 2, 91 Phase 1, 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 319 | Active not recruiting 319 |
| Phase 1 | 91 | Active not recruiting 91 |
| Phase 3 | 12 | Active not recruiting 12 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment ivonescimab plus EGFR-TKI. - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Active not recruiting | Shandong Cancer Hospital and Institute | 36 | 2026-01-01 | 2026-06-25 |
| An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment Lurbinectedin, Radiation Therapy - Small Cell Lung Carcinoma | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 9 | 2025-12-31 | 2026-06-16 |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Nivolumab, Ipilimumab, Carboplatin - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 76 | 2025-09-19 | 2026-05-14 |
| Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC Sacituzumab tirumotecan, Anlotinib - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV | Phase 2 | Active not recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-08-13 | 2026-07-14 |
| Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Zelenectide pevedotin - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | BicycleTx Limited | 73 | 2025-07-18 | 2026-04-15 |
| Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms ETOPOSIDE - Usual, ETOPOSIDE - Study - Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2025-07-16 | 2026-08-27 |
| JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC JS207, Pemetrexed injection, Platinum - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 69 | 2025-06-19 | 2026-08-04 |
| Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） Radiotherapy or Surgery, Standard Medical Therapy - OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Shanghai Chest Hospital | 97 | 2025-06-03 | 2025-07-22 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 Trabedersen, Pembrolizumab - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Nebraska | 45 | 2025-05-12 | 2026-09-25 |
| A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer ES102, Toripalimab - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Elpiscience (Suzhou) Biopharma, Ltd. | 30 | 2025-04-30 | 2026-10-20 |
| Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine - Lung Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2025-03-20 | 2026-10-13 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC Tarlatamab - Small Cell Lung Cancer (SCLC) | Phase 2 | Active not recruiting | Amgen | 252 | 2025-02-26 | 2026-10-06 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors BMS-986490, Bevacizumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 360 | 2025-02-12 | 2026-09-01 |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) M9140 - Solid Tumors, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 184 | 2025-01-29 | 2026-10-22 |
| Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC Cemiplimab, Placebo - NSCLC Stage IV | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 136 | 2025-01-14 | 2026-06-23 |
| A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer Uliledlimab, Sintilimab, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | TJ Biopharma Co., Ltd. | 150 | 2025-01-09 | 2026-01-30 |
| A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Cemiplimab, Platinum-based chemotherapy, REGN7075 - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 120 | 2024-11-18 | 2026-08-24 |
Showing 20 of 319. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (228) · Lung Neoplasms (92) · Small Cell Lung Carcinoma (40) · Colorectal Neoplasms (24) · Melanoma (22) · Neoplasms (20) · Breast Neoplasms (18) · Neoplasm Metastasis (17) · Squamous Cell Carcinoma of Head and Neck (17) · Pancreatic Neoplasms (15) · Ovarian Neoplasms (14) · Stomach Neoplasms (14) · Carcinoma, Renal Cell (13) · Brain Neoplasms (12) · Carcinoma, Hepatocellular (11)
Neoplasms by Site (315) · Respiratory Tract Neoplasms (309) · Respiratory Tract Diseases (306) · Lung Diseases (302) · Neoplasms (299) · Bronchial Neoplasms (257) · Carcinoma, Bronchogenic (257) · Lung Neoplasms (220) · Neoplasms by Histologic Type (84) · Neoplasms, Glandular and Epithelial (68) · Carcinoma (55) · Digestive System Diseases (51) · Digestive System Neoplasms (50) · Gastrointestinal Diseases (42)
pembrolizumab (54) · Carboplatin (52) · Cisplatin (34) · Nivolumab (33) · Pemetrexed (33) · durvalumab (28) · osimertinib (28) · Paclitaxel (26) · atezolizumab (17) · Docetaxel (16) · Radiotherapy (16) · Ipilimumab (15) · Etoposide (12) · Specimen Handling (12) · Disulfides (11)
National Cancer Institute (NCI) (26) · M.D. Anderson Cancer Center (21) · AstraZeneca (19) · Sichuan Baili Pharmaceutical Co., Ltd. (7) · Memorial Sloan Kettering Cancer Center (6) · Fundación GECP (5) · Eli Lilly and Company (4) · Janssen Research & Development, LLC (4) · Merck Sharp & Dohme LLC (4) · Novartis Pharmaceuticals (4) · Regeneron Pharmaceuticals (4) · Amgen (3) · Bristol-Myers Squibb (3) · Dana-Farber Cancer Institute (3) · ETOP IBCSG Partners Foundation (3)
United States (207) · China (79) · Spain (75) · France (67) · South Korea (55) · Italy (50) · Canada (44) · Germany (37) · United Kingdom (35) · Japan (34) · Australia (31) · Taiwan (31) · Belgium (30) · Netherlands (29) · Turkey (Türkiye) (23)
Caicun Zhou, PHD (3) · Mariano Provencio, MD (3) · Anne S Tsao (2) · Arun Rajan, M.D. (2) · Ferdinandos Skoulidis, MD,PHD (2)
PMID 34393061, PMID 32027845, PMID 37934000, PMID 40179330, PMID 22225488, PMID 22285199, PMID 24327518, PMID 26586415, PMID 27424289, PMID 27825638, PMID 28053024, PMID 28672195, PMID 28729154, PMID 29118225, PMID 29383130, PMID 29658848, PMID 29846250, PMID 29906251, PMID 29982279, PMID 30405781, PMID 30883000, PMID 30943124, PMID 30975030, PMID 31101621, PMID 31236847, PMID 31386610, PMID 31399043, PMID 31401903, PMID 31533931, PMID 31682550, PMID 31754049, PMID 31831767, PMID 31838007, PMID 31838015, PMID 31882719, PMID 31894292, PMID 31969335, PMID 31980466, PMID 32359091, PMID 32463741, PMID 32469185, PMID 32771088, PMID 32798130, PMID 32846060, PMID 32846061, PMID 32919526, PMID 33048619, PMID 33067126, PMID 33122578, PMID 33362722
2023 (27), U10CA180888 (9), 2018 (6), 2019 (6), 2015 (5), 2017 (4), UM1CA186689 (4), UM1CA186691 (4), 2025 (3), U10CA032102 (3), U10CA180820 (3), 2016 (2), UM1CA186709 (2), ZIABC011078 (2), 2014 (1)